Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) in Preclinical Studies of Antivascular Treatments. - Wikidata - wikimedia - TriplyDB

Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) in Preclinical Studies of Antivascular Treatments.

Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) in Preclinical Studies of Antivascular Treatments.

http://www.wikidata.org/entity/Q38168371

about

Towards multidimensional radiotherapy: key challenges for treatment individualisation.In vivo spectral and fluorescence microscopy comparison of microvascular function after treatment with OXi4503, Sunitinib and their combination in Caki-2 tumors.Quantitative Evaluation of Tumor Early Response to a Vascular-Disrupting Agent with Dynamic PET.Characterization of early neovascular response to acute lung ischemia using simultaneous (19)F/ (1)H MR molecular imaging.Hypoxia as a Biomarker and for Personalized Radiation Oncology.Diffusion-compensated tofts model suggests contrast leakage through aneurysm wall.Identification of the S100 fused-type protein hornerin as a regulator of tumor vascularity.The potential of hyperpolarized 13C magnetic resonance spectroscopy to monitor the effect of combretastatin based vascular disrupting agents.Assessment of active and inactive sacroiliitis in patients with ankylosing spondylitis using quantitative dynamic contrast-enhanced MRI.Starvation tactics using natural compounds for advanced cancers: pharmacodynamics, clinical efficacy, and predictive biomarkers.

P2860

Q27687218-C7084DB8-F0BE-4130-9E4F-0DFA8477463B Q33738607-6F65CF23-204C-43FF-B006-C642EDC9952C Q37568306-72BC91DF-D221-453A-B9DE-D097DBEF0029 Q37626285-5E477212-BFC2-49AC-A2A4-2A8E02D1349D Q38869433-CD39E94E-2B34-45A7-9CFC-A4F05C34A96F Q39005549-74EB8BDC-B275-48F2-AF20-1BC49FB7C63F Q41701383-C720C7CA-C957-4A31-A9CC-8EA787BF6C88 Q47792667-B60E5236-8408-4424-B2B2-81379A64BE8F Q51058288-8EF39CEE-0A22-4C33-ADB8-90C7EEC62E82 Q55365628-D49E0279-9992-4891-92A1-FE4162E65C11

P2860

Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) in Preclinical Studies of Antivascular Treatments.

http://www.wikidata.org/entity/Q38168371

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

Dynamic Contrast-Enhanced Magn ...... es of Antivascular Treatments.

@en

type

label

Dynamic Contrast-Enhanced Magn ...... es of Antivascular Treatments.

@en

prefLabel

Dynamic Contrast-Enhanced Magn ...... es of Antivascular Treatments.

@en

P1433

Q38168371-ED6ADF35-4E9E-4DEB-BFAD-64DCDC07C6D4

P1476

Q38168371-770137ED-9C9D-45D7-8A33-4D538355BEB1

P2093

Q38168371-1A849B66-ECF1-4CA9-A3E3-B1509D847407

Q38168371-B059FCFE-CEDA-47FE-842E-984F528EA6D9

P2860

Q38168371-023809A8-C4CB-482C-AA70-865A12AA000E

Q38168371-0349481D-C7E8-4532-B5EB-58A8ACDFBC66

Q38168371-034AC0FA-C17F-41EC-9630-CDB9C6FAD6F5

Q38168371-0869D7F8-2C73-4D6E-9E75-2C04322377F1

Q38168371-0BFE2A7B-29F9-415A-9BDA-BD3263731BDE

Q38168371-0F3865FF-0A18-4225-8B77-0FEBF263A969

Q38168371-10572254-BAB3-41B3-9323-4C13520C0B13

Q38168371-105DCA9F-9BC7-41C9-8231-B125AEF063F2

Q38168371-168E518C-6EA3-4463-8248-658BADB1590C

Q38168371-1C94D422-29AF-463C-BCED-F788E3F1EEB1

P304

Q38168371-E9D6F7AE-A755-4F03-9CE6-E2B68AE4C766

P31

Q38168371-39E78C90-A9D7-4FC6-80AE-01A26CF00131

P356

Q38168371-76E7A53C-D6C3-44A5-B8B5-4F25BF99D011

P433

Q38168371-75D07E2F-650B-4A0E-9B61-6D4D8D8DB73F

P478

Q38168371-95D2CEE6-2E62-4F38-8228-65A14D7088C3

P50

Q38168371-69D05A85-AE11-4E25-A0C3-89A7506C74F1

P577

Q38168371-4ACD4EFA-DEB2-434F-A855-73328F7FFD2A

P5875

Q38168371-1173AF72-E85C-4CBA-95AB-DCDD89B3151D

P698

Q38168371-0AADB429-7D66-4EEF-859A-0D165FD96A77

P932

Q38168371-48721910-9A11-4C84-A78E-C313C07C7B0A

P356

PHARMACEUTICS4040563

P1433

P1476

Dynamic Contrast-Enhanced Magn ...... ies of Antivascular Treatments

@en

P2093

Thomas Nielsen

http://www.w3.org/2001/XMLSchema#string

Thomas Wittenborn

http://www.w3.org/2001/XMLSchema#string

P2860

The biology of VEGF and its receptors

Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. Generalizations

Antivascular effects of combretastatin A4 phosphate in breast cancer xenograft assessed using dynamic bioluminescence imaging and confirmed by MRI

AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging

Hypoxia--a key regulatory factor in tumour growth

Regulation of angiogenesis by hypoxia: role of the HIF system

Angiogenesis as a therapeutic target

Tumorigenesis and the angiogenic switch

Monitoring antivascular therapy in head and neck cancer xenografts using contrast-enhanced MR and US imaging

Key factors in the acquisition of contrast kinetic data for oncology.

P304

563-589

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3390/PHARMACEUTICS4040563

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P50

Michael R. Horsman

P577

2012-11-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

259153587

http://www.w3.org/2001/XMLSchema#string

P698

24300371

http://www.w3.org/2001/XMLSchema#string

P932

3834929

http://www.w3.org/2001/XMLSchema#string